Chronic A2A antagonist treatment alleviates parkinsonian locomotor deficiency in MitoPark mice

Neurobiology of Disease

Volumn 40, Issue 2, 2010, Pages 460-466

  Marcellino, Daniel ^a   Lindqvist, Eva ^a   Schneider, Marion ^b   Müller, Christa E ^b   Fuxe, Kjell ^a   Olson, Lars ^a   Galter, Dagmar ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Dopamine; Drug induced locomotor activity; HPLC; L DOPA; Mass spectrometry; Parkinson's disease; Spontaneous locomotion; Striatum; Western blot

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 5 HYDROXYINDOLEACETIC ACID; ADENOSINE A2A RECEPTOR ANTAGONIST; BENSERAZIDE PLUS LEVODOPA; DOPAMINE; HOMOVANILLIC ACID; MONOAMINE; MSX 3; SEROTONIN; SODIUM CHLORIDE; UNCLASSIFIED DRUG; ADENOSINE A2 RECEPTOR ANTAGONIST; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MSX 3 COMPOUND; XANTHINE DERIVATIVE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DOPAMINERGIC NERVE CELL; DRUG ACCUMULATION; DRUG BRAIN LEVEL; DRUG DOSE COMPARISON; DRUG MEGADOSE; FEMALE; GENETIC MODEL; LOCOMOTION; LOW DRUG DOSE; MALE; MOUSE; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; TREATMENT DURATION; ANIMAL; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECT; METABOLISM; MOTOR ACTIVITY; MOUSE STRAIN; PATHOPHYSIOLOGY; TIME; TREATMENT OUTCOME;

ADENOSINE A2 RECEPTOR ANTAGONISTS; ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGENTS; LEVODOPA; MICE; MICE, INBRED STRAINS; MOTOR ACTIVITY; PARKINSON DISEASE; TIME FACTORS; TREATMENT OUTCOME; XANTHINES;

EID: 78650416384     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2010.07.008     Document Type: Article

References (29)

1. Bara-Jimenez W., et al. Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology 2003, 61:293-296.
2. Calon F., et al. Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias. Brain 2004, 127:1075-1084.
3. Chase T.N., et al. Translating A2A antagonist KW6002 from animal models to parkinsonian patients. Neurology 2003, 61:S107-S111.
4. Chen J.F., et al. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J. Neurosci. 2001, 21:RC143.
5. Ekstrand M.I., et al. Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proc. Natl Acad. Sci. USA 2007, 104:1325-1330.
6. Fahn S. Does levodopa slow or hasten the rate of progression of Parkinson's disease. J. Neurol. 2005, 252 Suppl 4:IV37-IV42.
7. Fenu S., et al. Adenosine A2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats. Eur. J. Pharmacol. 1997, 321:143-147.
8. Fernandez H.H., et al. Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial. Parkinsonism Relat. Disord. 2010, 16(1):16-20.
9. Ferre S., et al. Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes. Proc. Natl Acad. Sci. USA 1991, 88:7238-7241.
10. Fredholm B.B., et al. Effect of some phosphodiesterase inhibitors on central dopamine mechanisms. Eur. J. Pharmacol. 1976, 38:31-38.
11. Fuxe K., et al. Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson's disease. Neurology 2003, 61:S19-S23.
12. Fuxe K., et al. Adenosine A(2A) receptors, dopamine D(2) receptors and their interactions in Parkinson's disease. Mov. Disord. 2007, 22:1990-2017.
13. Fuxe K., Ungerstedt U. Action of caffeine and theophyllamine on supersensitive dopamine receptors: considerable enhancement of receptor response to treatment with DOPA and dopamine receptor agonists. Med. Biol. 1974, 52:48-54.
14. Galter D., et al. MitoPark mice mirror the slow progression of key symptoms and L-DOPA response in Parkinson's disease. Genes Brain Behav. 2010, 9(2):173-181.
15. Hauser R.A. New considerations in the medical management of early Parkinson's disease: impact of recent clinical trials on treatment strategy. Parkinsonism Relat. Disord. 2009, 15(Suppl 3):S17-S21.
16. Hauser R.A., et al. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology 2003, 61:297-303.
17. Hockemeyer J., et al. Multigram-scale syntheses, stability, and photoreactions of A2A adenosine receptor antagonists with 8-styrylxanthine structure: potential drugs for Parkinson's disease. J. Org. Chem. 2004, 69:3308-3318.
18. Ikeda K., et al. Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease. J. Neurochem. 2002, 80:262-270.
19. Jankovic J. Are adenosine antagonists, such as istradefylline, caffeine, and chocolate, useful in the treatment of Parkinson's disease?. Ann. Neurol. 2008, 63:267-269.
20. Jenner P., et al. Adenosine, adenosine A 2A antagonists, and Parkinson's disease. Parkinsonism Relat. Disord. 2009, 15:406-413.
21. Kanda T., et al. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann. Neurol. 1998, 43:507-513.
22. Karcz-Kubicha M., et al. Involvement of adenosine A1 and A2A receptors in the motor effects of caffeine after its acute and chronic administration. Neuropsychopharmacology 2003, 28:1281-1291.
23. Nagel J., et al. Effects of an adenosine A2A receptor blockade in the nucleus accumbens on locomotion, feeding, and prepulse inhibition in rats. Synapse 2003, 49:279-286.
24. Ross G.W., et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 2000, 283:2674-2679.
25. Sauer R., et al. Water-soluble phosphate prodrugs of 1-propargyl-8-styrylxanthine derivatives, A(2A)-selective adenosine receptor antagonists. J. Med. Chem. 2000, 43:440-448.
26. Schwarzschild M.A., et al. Targeting adenosine A2A receptors in Parkinson's disease. Trends Neurosci. 2006, 29:647-654.
27. Svenningsson P., et al. Distribution, biochemistry and function of striatal adenosine A2A receptors. Prog. Neurobiol. 1999, 59:355-396.
28. Tanganelli S., et al. Striatal plasticity at the network level. Focus on adenosine A2A and D2 interactions in models of Parkinson's Disease. Parkinsonism Relat. Disord. 2004, 10:273-280.
29. Yang M., et al. Characterization of the potency, selectivity, and pharmacokinetic profile for six adenosine A2A receptor antagonists. Naunyn. Schmiedebergs Arch. Pharmacol. 2007, 375:133-144.